Sikora Figure S1. The effects of sulfenamide and sulfonamide derivatives of metformin on selected parameters of plasma and vascular haemostasis*. * Based on the results of our previous papers; Markowicz-Piasecka et al., 2017, Eur J Pharm; Markowicz-Piasecka et al., 2018, Chem-Biol Int; Markowicz-Piasecka et al., 2019, Sci Rep.
Compounds 2 -4 Basic metformin (2.0 eq.), and commercial sulfonyl chlorides (1.0 eq.) were dissolved in anhydrous CH2Cl2 and stirred under argon for 3 h. The solvent was evaporated under reduced pressure and the residue was purified by flash column chromatography eluting with 0-30% MeOH in CH2Cl2 to obtain the compounds 1-3 (19-72%).
Spectroscopic characterization of compounds 1 -4
N 1 ,N 1 -dimethyl-N 4 -(butylthio)-bisguanidine (1) 1 H NMR (CD3OD): δ ppm 3.04 (s, 6H), 2.75 (t, 3JHH = 7.4 Hz, 2H), 1.68-1.60 (m, 2H), 1.51-1.43 (m, 2H), 0.95 (t, 3JHH = 7.4 Hz, 3H); 13 C NMR (CD3OD): δ ppm 161. 45, 160.62, 40.02, 38.06 (2C), 30.94, 22.72, 14. 02. MS (ESI+) for C8H20N5S (M)+: Calcd 218.33, Found 218.13. N 1 ,N 1 -Dimethyl-N 4 -(2-nitro-4-(trifluoromethyl)benzenesulfonamide)-bisguanidine (2) Prepared from 2-nitro-4-(trifluoromethyl)benzenesulfonyl chloride. 1 H NMR ((CD3)2SO): δ ppm 7.45 (s, 1H), 8.28 (d, 3 JHH=8.2 Hz, 1H), 8.16 (d, 3 JHH=8.2 Hz, 1H), 8.02-7.88 (bs, 2H), 7.24-6.62 (bs, 2H), 2.92 (s, 6H); 13 C NMR (CDCl3): δ ppm 158. 93, 158.45, 147.49, 139.45, 132.53, 130.37, 128.80, 123.64, 121.49, 36.69 (2 C) . MS (ESI+) for C11H14F3N6O4S (M+H)+: Calcd 383.33, Found 383.03. Anal. Calcd for (C11H13F3N6O4S): C, 34.56; H, 3.43; N, 21.98; S, 8.39; Found: C, 34.76; H, 3.09; N, 21.57; S, 8.20 . N 1 ,N 1 -Dimethyl-N 4 -(4-nitrobenzenesulfonamide)-bisguanidine (3) Prepared from 4-nitrobenzenesulfonyl chloride. 1 H NMR ((CD3)2SO): δ ppm 8.33 (d, 3 JHH=8.8 Hz, 2H), 8.02 (d, 3 JHH=8.8 Hz, 2H), 8.08-7.79 (bs, 2H), 7.20-6.94 (bs, 1H), 6.90-6.62 (bs, 1H), 2.91 (s, 6H); 13 C NMR ((CD3)2SO): δ ppm 159. 52, 158.32, 149.80, 148.88, 127.30 (2 C), 124.24 (2 C), 36.61 (2 C). MS (ESI+) for C10H15N6O4S (M+H)+: Calcd 314.33, Found 315.10. Anal. Calcd for (C10H14N6O4S): C, 38.21; H, 4.49; N, 26.74; S, 10.20; Found: C, 38.32; H, 4.19; N, 26.59; S, 9.96 . N 1 ,N 1 -Dimethyl-N 4 -(2-nitrobenzenesulfonamide)-bisguanidine (4) Prepared from 2-nitrobenzenesulfonyl chloride. 1 H NMR ((CD3)2SO): δ ppm 8.09-8.04 (m, 1H), 8.29-7.88 (bs, 2H), 7.87-7.83 (m, 1H), 7.78-7.74 (m, 2H), 7.30-6.92 (bs, 1H), 6.91-6.52 (bs, 1H), 2.93 (s, 6H); 13 C NMR ((CD3)2SO): δ ppm 159. 07, 158.38, 147.38, 135.71, 132.90, 131.87, 128.90, 123.85, 36.62 (2 C) . MS (ESI+) for C10H15N6O4S (M+H)+: Calcd 314.33, Found 315.10. Anal. Calcd for (C10H14N6O4S): C, 38.21; H, 4.49; N, 26.74; S, 10.20; Found: C, 38.56; H, 4.09; N, 26.37; S, 10.35 . Figure S2 . The effects of compounds 1 -4 on the viability of HUVEC cells. The cells were incubated with compounds at various concentrations (0.006 -10.0 μmol/mL) for 24 hours, and the viability of the cells was measured spectrophotometrically using the WST-1 test. The results are presented as mean ± SD, n = 6 -8. One-way Anova analysis revealed significant differences in HUVEC viability at various concentrations (* p < 0.05; ** p < 0.01; *** p < 0.001). Figure S3 . The effects of compounds 1 -4 on the viability of AoSMC cells. The cells were incubated with compounds at various concentrations (0.006 -3.0 μmol/mL) for 24 hours, and the viability of the cells was measured spectrophotometrically using the WST-1 test. The results are presented as mean ± SD, n = 8. One-way Anova analysis revealed significant differences in AoSMCs viability at various concentrations (* p < 0.05; ** p < 0.01; *** p < 0.001).
Compound 1 Figure S4 . Inhibition of cell migration in the presence of biguanides. AoSMC cells migration was evaluated using wound healing assay. Representative cell images are shown for control samples and biguanides at the concentration of 1.5 (metformin) or 1.0 μmol/mL (compounds 1-4) . Cells were photographed using an inverted microscope at the indicated times (t = 0, 8, 24 h); 100× magnification. The results are presented as mean ± standard deviation (SD) of the wound width, n = 10-12 at various time points (T0, 2 hours (T2), 4 hours (T4), 8 hours (T8) and 24 hours (T24)). The values given in bold represent statistically significant (p < 0.05) changes versus control. Smooth muscle cells were treated with various concentrations of biguanides for 24 hours followed by staining with PE-CD54 antibody. The concentration for the studies were chosen on the basis of results collected in viability assay. The results are presented as mean ± standard deviation (SD), n = 3-6. The values given in bold represent statistically significant (p < 0.05) changes versus respective controls. Viability test using double staining with Annexin V and priopidine Iodide: Representative histograms of unstimulated HUVEC cells (control). Cytogram on the left side: Forward and side scatter plot of HUVEC cells. The living cells were marked with gate A. Cytograms in the centre: a forward scatter width (FSC-W) vs. forward scatter area (FSC-A) of the cells gathered in gate A. Singe cells were marked with gate B (ca. 82.99%). Cytograms on the right side: Annexin V FITC-A (x-axis) vs propidium iodide (y-axis) plots from the gated cells (B) show the populations corresponding to living cells (Annexin V(-) and PI (-)) (D--) -84.32%; early apoptotic cells (Annexin V (+) and PI (-)) (D+-) -9.66%, late-apoptotic cells (Annexin V(+) and PI (+)) (D++) -4.63%, and necrotic cells (Annexin V (-) and PI (+)) (D-+) -1.39%.
